Intercept Pharmaceuticals has voluntarily withdrawn Ocaliva (obeticholic acid), an oral therapy used to treat certain adults with primary biliary cholangitis (PBC), from the U.S. market following a request from the U.S. Food and Drug Administration (FDA). The FDA has also placed a clinical hold on all Intercept-sponsored Ocaliva clinical trials underway in the U.S., the […] The post PBC treatment Ocaliva leaves U.S. market amid safety concerns appeared first on Liver Disease News.
